Niacin on Immune Activation : a Proof-of-concept Study

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
HIV
Interventions
DRUG

Niacin

"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."

DRUG

Niacin

"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."

Trial Locations (1)

H2W1T7

Montreal Chest Institute, Montreal

All Listed Sponsors
collaborator

CIHR Canadian HIV Trials Network

NETWORK

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02018965 - Niacin on Immune Activation : a Proof-of-concept Study | Biotech Hunter | Biotech Hunter